Cell proliferation in canine, feline, and equine tumors was evaluated using immunohistochemical detection of in vitro 5-bromodeoxyuridine (BrdU) incorporation, proliferating cell nuclear antigen (PCNA), and interchromatin-associated antigen (p105). Ten tumors in each species were analyzed. The tumor proliferative fraction (PF) was defined as the percentage of labeled nuclei for 5,000 tumor nuclei counted. Immunoreactivity was observed with all techniques in all species. A good correlation was observed between the proliferative fractions measured with the BrdU (PF BrdU ) and PCNA (PF PCNA ) techniques (r s = 0.523, P = 0.0026). There was no correlation between the PFs measured with the BrdU (PF BrdU ) and p105 (PF P105 ) techniques. Using the median values obtained from the different approaches as cutoff points to define slowly and rapidly proliferating tumors, there was an 80% agreement (P = 0.009) between PF BrdU and PF PCNA and no agreement between PF BrdU and PF P105 The results of this study indicate that both BrdU and PCNA labeling methods can be used reliably for identifying proliferating cells in animal tumors. In addition, PCNA could be used to replace the BrdU method to assess tumor proliferative fraction because it does not require pretreatment of tissues.
Cellular proliferation is an important characteristic after in vitro or in vivo incorporation of BrdU has of solid tumor behavior because it is directly linked to been found in human and canine tissues. 7 , 38 The techthe rate of tumor growth. Cell kinetic parameters are nique can be used on histological preparations, and its becoming increasingly important as a potential prog-specificity is independent of tissue and species. Hownostic indicator and as a basis for altering conventional ever, a significant drawback of both techniques has therapy schedules in cancer treatment. 11, 25, 26, 33, 35, 36, 39 been the need for fresh tissue to be incubated with a Determination of cell kinetic parameters includes mea-nucleotide. Plow cytometry has also been used, but it surements of both the fraction of proliferating cells and is a degradative technique that results in loss of tissue doubling times, i.e., cell cycle time and potential and architecture, prohibiting simultaneous analysis of hiseffective doubling times. 11, 31 topathology and cell proliferation features. 15, 19 The proliferative fraction (growth fraction) has prognostic and therapeutic implications in several human tumors for radiotherapy and chemotherapy.1,5,9, 18, 23, 29, 20, 35, 41, 42 The standard techniques for measuring cellular proliferative activity are the detection of DNA precursors such as tritiated thymidine ( 3 HTdR) or 5'-bromodeoxyuridine (BrdU), which are incorpo-. rated into the nuclear DNA during S phase. 15 BrdU is used as an exogenous antigen (BrdU) detected by immunochemical techniques in nuclei by an anti-BrdU monoclonal antibody. 14 
Good agreement between labeling indices measured
Recently, immunohistochemical methods have emerged that allow for the study of nucleus-associated proliferation markers to assess proliferation in tissues. 15, 16, 27, 43 These methods have the advantage of preserving the spatial orientation of proliferating cells in histological sections. Several endogenous cell proliferation markers can be recognized by monoclonal antibodies on tissue sections. 43 Proliferating cell nuclear antigen (PCNA) and interchromatin-associated antigen (p105) are 2 nuclear antigens that can be used to detect proliferating cells in conventionally fixed and processed human tissues. The goal of this study was 2-fold: 1) to analyze the immunoreactivity of canine, feline, and equine spontaneous tumors comparing the techniques using the monoclonal antibodies (MAbs) anti-PCNA and antip 105 with that using BrdU and 2) to determine whether BrdU technique, which requires pretreatment of the tissues. The BrdU technique was used as a reference because of its specificity and reliability for in situ immunohistochemical detection of S-phase cells on tissue sections. 24
Materials and methods
Tissue samples. Cellular proliferative activity was determined in 10 canine, 10 feline, and 10 equine tumors. Tumors in dogs included tumors of the oral cavity (1 acanthomatous epulis, 1 malignant melanoma, 1 squamous cell carcinoma, 1 fibrosarcoma), squamous cell carcinoma of the nasal planum (1), mammary adenocarcinoma (1), perianal tumors (1 squamous cell carcinoma, 1 anal sac adenocarcinoma), and cutaneous sarcomas (1 fibrosarcoma, 1 myxosarcoma). Tumors in cats included tumors of the oral cavity (1 squamous cell carcinoma, 1 malignant melanoma, 1 fibrosarcoma), squamous cell carcinoma of the nasal planum (5), mammary adenocarcinoma (1), and cutaneous fibrosarcoma (1). Tumors in horses included squamous cell carcinoma of the male (1 penis, 1 prepuce) and female (1 vulva) genitalia and the eyelids (1) and sarcoid located on the eyelids (4), scrotum (1) and ear pinna (1). Freshly excised tumor specimens were obtained in the operating room at the UC-Davis Veterinary Medical Teaching Hospital. Immediately after excision, an aliquot of fresh tumor tissue was processed for BrdU incorporation then fixed in formalin. The remaining fresh tissue was fixed in formalin for histologic examination and immunohistochemical studies using PCNA and p105. Tissue samples were processed and embedded in paraffin within 24 hr.
In vitro BrdU incorporation. For in vitro BrdU incorporation, tissue was cut into small fragments, placed in tissue culture medium (RPMI) a containing 100 µM BrdU b and incubated 2 hr at 37 C in a humidified atmosphere containing 5% CO 2 . 24 The tissue was then fixed with formalin, processed, and embedded in paraffin.
Immunostaining methods. Four-micrometer-thick sections were cut and mounted on poly-L-lysine-coated glass slides. c For each tissue (with or without incorporated BrdU), 6 sections were used per technique; 1 slide was used as a negative control. Sections were deparaffinized in xylene, hydrated through gradients of alcohol, and denatured with 2 M HCl. 24 The sections were then processed with a primary MAb, anti-BrdQ d anti-PCNA, e or anti-p105. f Development was performed with the StrAviGen f super sensitive universal immunostaining kit. The sections were then lightly counterstained with hematoxylin. Negative controls were processed by substituting the negative control antibody (murine Ig) f for the primary antibody. Cell block preparation of cell lines (B16 mouse melanoma and A549 human lung carcinoma cells) with known doubling times were used as initial titration and daily run positive controls.
Labeling index. Fifteen slides per tumor were read after randomization and coding. Cells were counted on a highpower field (400 x) using an ocular micrometer (10 x 10 squares). On each tissue section, a labeling index (LI) was calculated for each technique as percentage of labeled nuclei measured on 5 fields of view. Each field of view contained approximately 200 tumor cells with a high density of labeled nuclei, yielding a total of 1,000 tumor cells counted. A proliferative fraction (PF) per tumor was calculated as the average LI obtained from 5 slides, yielding a total of at least 5,000 cells counted per tumor sample. A tumor proliferative fraction was calculated with the BrdU (PF BrdU ), the PCNA (PF PCNA ), and the p105 (PF P105 ) techniques.
Data analysis. The species specificity of each PF index was tested using an analysis of variance for repeated measures. 10 The effects of the number of slides (3, 4, 5) read per tissue sample on inter-and intratumor variability were analyzed in 2 ways. Intra-and inter-tumor variability were assessed independently using the coefficient of variation (CV: standard deviation/mean). The intertumoral coefficient of variation was calculated assuming that each tumor within a population of tumors is homogenous with respect to LI, but there is heterogeneity between tumors for PF. The intratumoral CV was calculated assuming that each tumor within a population of tumors is homogenous with respect to PF, but there is heterogeneity within an individual tumor for LI. To measure intertumor differences in proliferative activity, tumors were categorized as either slowly or rapidly proliferating. According to each technique, the median values of PFs were used as cutoff values to divide tumors into subsets of slowly or rapidly proliferating tumors.
Differences in PF measured by the different methods were analyzed by the Wilcoxon signed-rank test. 10 The Spearman's rank test was used to analyze the correlation between PFs measured by the different labeling techniques. 10 The kappa test was used to evaluate the grade of association between BrdU PF and the PF of the other 2 techniques. 10
Results
Positive staining of BrdU, PCNA, and p105 antigenantibody complexes was observed in all tissues examined. The tumor PFs measured with the 3 techniques are summarized in Fig. 1 . For each technique, no statistical difference in immunoreactivity was found among cats, dogs, and horses. When all tumors were pooled, the average values of PF BrdU , PF PCNA , and PF P105 were significantly different; PF BrdU was the lowest and PF P105 was the highest. The staining patterns of positive cells varied from technique to technique. The BrdUpositive cells showed either granular or slightly punctate dark nuclear staining (deep red). The PCNApositive cells showed granular nuclear staining. The p105-positive cells showed punctate nuclear staining. Staining in both BrdU-and p105-positive cells was darker than in PCNA-positive cells. Occasionally, cytoplasmic staining was observed in p105-positive cells.
Cell labeling varied greatly from 1 area to another on the same slide. The inter-and intratumoral variability of LI was a function of the technique used and the number of cells counted. Variability was the largest for the BrdU technique and the smallest for the p105 technique (Fig. 2) .
There was a significant correlation (r s = 0.523, P = 0.0026) between PF BrdU and PF PCNA ; there was no significant correlation (P > 0.05) between PF BrdU and PF P105 . The average (±SD) ratio of PF BrdU to PF PCNA , which represents the S-phase fraction size, 32 was 0.43 (±0. 18) . Median values of PFs were used as cutoff points to define low and high PFs. The cutoff points for PF BrdU , PF PCNA , and PF P105 were 7%, 18%, and 35%, respectively. Using these criteria, there was an 80% agreement (K = 0.516, P = 0.009) between BrdU and PCNA but no agreement (K = -0.290) between BrdU and p105.
Discussion
Positive staining of BrdU, PCNA, and p105 antigenantibody complexes was observed in all tissues examined. The staining patterns of positive cells varied from technique to technique. No statistical difference of immunoreactivity was found between labeling indexes measured for different species, i.e., cat, dog, and horse. Antigen preservation, epitope masking, intrinsic cell-cycle length, and antigen half-life are factors that may contribute to immunostaining intensity. 13, 32 The intrinsic sensitivity of the detection system also influences antigen threshold visualization. In the present study, the use of the supersensitive biotin-streptavidin immunodetection system allowed an increased staining intensity and more efficient use of the antibody. The system is available in a kit and is supplied with an improved link and label antibody, which maximizes the signal generated by the antibody-antigen complex.
Tumor proliferative fractions measured with the 3 techniques are comparable to values previously published on human and murine tissues. 21, 24, 34, 37, 38, 41 Large differences between the proliferation indices measured with each technique were observed. These differences probably are due to inherent differences in the biology of these markers rather than to technical artifacts. When the BrdU assay is used, it is easy to identify the nature of the biologic process measured. BrdU is only incorporated during S-phase and can be detected at low levels. PCNA and p105 immunostaining measure different components of the cell cycle. PCNA and p105 are nuclear antigens expressed solely or predominantly in proliferating cells. The maximum amount of nuclear antigen produced may vary among tumors, and the portion of the cell cycle during which it is detectable may also vary. PCNA is a 36-kD auxiliary protein of DNA polymerase delta. 3 PCNA expression levels increase from late G1 phase, with a peak during S phase, and decrease in G2/M phases. 20 p105 is a 105-kD nuclear protein involved in RNA synthesis 6 and its expression is present with variable intensity during all but the Go phase of the cell cycle. 33, 41 Inter-and intratumor variability was a function of the technique used and the number of cells counted on 3, 4, and 5 slides. Inter-and intratumoral differences in tumor PFs assessed with the standard BrdU technique were best matched with the PCNA technique. Intratumoral variability underscores the critical importance of representative sampling. The sample size count and its relationship to the margin of error determine the ability to resolve significant differences between 2 tumors, between replicate measurements of the same tumor, and between comparable studies. The number of slides required for each technique is a function of the sample variability needed to distinguish inter-or intratumor variability. In the sample of tu-mors evaluated in the present study, increasing the number of slides from 3 to 5 did not improve the ability to detect the inter-tumor differences; the intertumoral CV did not differ significantly (Fig. 2) . However, there was a trend for detecting larger intratumor differences with an increasing number of slides; the intratumoral CV increased slightly with the number of slides read (Fig. 2) .
With any method of assessing cellular proliferation, the problem of heterogeneity within a tumor specimen must be considered. There are functionally and kinetically distinct populations in normal and tumor tissues. 17 Stem cells in tumors may represent the predominant biologically and therapeutically relevant population. 4, 22 The assessment of cell proliferation in different subpopulations characterized by a high labeling density may provide more information than counting all the cells in the sample as the denominator when calculating labeling indexes. Random sampling of fields of view was avoided because the mean value of such labeling indices does not reflect the actual growth potential of each tumor. Heterogeneity may extend to differences in kinetic indices in tumor samples from different sites, and this may have considerable therapeutic implications. 25 In situ determination on histological sections derived from different tumor areas allows analysis of tumor heterogenous complexity. In addition, it allows the verification of sampling adequacy and the correct and selective scoring of tumor cells in different areas.
The tumor PF PCNA appeared to be a good indicator of tumor PF when compared with the PF BrdU in animal tumors. The p105 LI did not appear to be useful for assessing cellular proliferation. These findings are consistent with previously reported studies on human or murine tissues. 15, 43 A good correlation has been reported between the tumor proliferative index measured with the PCNA technique and the S-phase fraction measured with the BrdU technique. 1, 8, 12, 21, 28, 37 The p105 technique on the other hand did not appear to be useful for assessing tumor PF, probably because of its high sensitivity. 32 The correlation found in this preliminary study between PF BrdU and PF PCNA needs to be confirmed by an examination of a large series of different tumor types and locations.
The immunoreactivity of PCNA in formalin-fixed, paraffin-embedded tissue makes PCNA labeling a very attractive technique to assess cell proliferation. The technique is easy to perform on routinely processed tissues. Cell kinetic data can be obtained from PCNA labeling in 2-3 days. As a result, the histopathologic findings and the cellular proliferative activity of the tumor are known at the same time prior to treatment, and a decision regarding treatment can be made. In addition. the techniaue allows retrospective studies on archival tissues. The interpretation of PCNA immunoreactivity necessitates a careful consideration of the length of fixation time of the tissues and the mode of preparation. 15 The PCNA technique could be a powerful tool for the routine study of cell proliferation in tumor biopsy. Information on cell cycle differences in various tumor types and possibly within patient subsets of the same tumor type is critical in the design of clinical trials that attempt to manipulate tumor cell kinetics. Further study is needed to validate the PCNA technique for reproducibility and prognostic relevance.
